Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term.
Photo by Dan Dennis on Unsplash
On November 18, JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly and Company to $1,150 from $1,050 while maintaining an Overweight rating after meetings with management. JPMorgan said the discussions reinforced its positive view on the company. The analyst noted that Lilly’s agreement with the Trump Administration to expand access to obesity medicines is a net positive.
Over the past five years, Eli Lilly and Company has seen major success with its weight loss drugs. The company holds a leading position in the new class of GLP-1 inhibitor drugs, which is significant given the prevalence of obesity and related health risks.
In Q3 2025, revenue rose 54% to $17.60 billion, driven by volume growth from Mounjaro and Zepbound. Reported EPS increased by $5.14 to $6.21, while non-GAAP EPS rose by $5.84 to $7.02. Pipeline progress included positive results in four Phase 3 trials of orforglipron for type 2 diabetes and obesity, with plans to submit for global regulatory approval for obesity treatment by year-end.
Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and markets medicines addressing medical needs in areas including diabetes, oncology, immunology, neurodegeneration, and pain.
READ NEXT: 15 Best Long Term Stocks to Buy According to Reddit and 13 Best Canadian Dividend Stocks to Buy and Hold for the Long Term.
